No safety concerns were identified [ 83 ], and one of the secondary endpoints, gait velocity, showed a trend toward improvement with GSK249320 compared with placebo.
1
—
—
No safety concerns were identified [ 83 ], and one of the secondary endpoints, gait velocity, showed a trend toward improvement with GSK249320 compared with placebo.